RE: Endo boffo quarter, up bigIf you were sitting on a successful and peer reviewed PIII bladder cancer drug and wanted to make a play for the IP owner, would you mention them anywhere and give them the airtime needed to make the acquisition price higher?
Without doubt, Endo is licking their chops at the (mis)management of BNC. I fully expect that each and every time they review the PIIIb trial, they wonder how they got so fortunate as to have to deal with a bunch of country-bumpkins intent more on lining their own personal pockets and those of the 'friends of BNC'(TM) than actually putting to rest a shareholder revolt and moving ahead with making the MCC protocol a true cancer beater. Instead we hire more VPs, pay them more for doing nothing, grant options on no merit and then claim bad markets when pressed on why things are piss poor with the SP.
Either way, Endo not saying anything about Urocidin or Bioniche is understandable and expected (especially given their overall performance and lack of need for anything sizzling)....why BNC fails to say anything is another matter and just plain pathetic.